Compare Stocks

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASNS Arsanis	$0.57	$3.11	$1.15 ▼ $28.69	$1.72M	0.87	213,906 shs	113,027 shs
IDRA Idera Pharmaceuticals		$0.50	$0.22 ▼ $8.67	$450.52M	1.25	464,030 shs	21,870 shs
PXS Pyxis Tankers	$4.91 +0.6%	$4.63	$3.25 ▼ $4.98	$51.55M	0.05	46,352 shs	45,563 shs
RENE Cartesian Growth Co. II	$11.22 +0.1%	$11.14	$10.55 ▼ $11.92	$242.59M	-0.02	56,950 shs	100,000 shs
SMMT Summit Therapeutics	$4.65 -2.7%	$4.07	$1.50 ▼ $5.39	$3.26B	-1.13	2.23 million shs	1.78 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASNS Arsanis	-5.00%	-5.00%	-38.04%	-52.10%	-85.38%
IDRA Idera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PXS Pyxis Tankers	+3.61%	+4.72%	+2.95%	+12.18%	+21.39%
RENE Cartesian Growth Co. II	+0.13%	+0.09%	+0.54%	+1.54%	+6.25%
SMMT Summit Therapeutics	-3.63%	+17.73%	+17.16%	+6.22%	+125.47%

Do This Today BEFORE Biden Wins in November (Ad)

Discover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).

Find out how you can too in this free video.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASNS Arsanis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PXS Pyxis Tankers	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	1.5471 of 5 stars	3.5	0.0	0.0	0.0	2.6	3.3	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASNS Arsanis	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A
PXS Pyxis Tankers	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	3.00	Buy	$7.50	61.29% Upside

Current Analyst Ratings

Latest ASNS, RENE, PXS, SMMT, and IDRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/7/2024	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
3/26/2024	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASNS Arsanis	$5.61M	0.31	N/A	N/A	$0.08 per share	7.13
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	0.29	$0.56 per share	N/A
PXS Pyxis Tankers	$45.47M	1.13	$4.27 per share	1.15	$9.50 per share	0.52
RENE Cartesian Growth Co. II	N/A	N/A	$0.40 per share	28.17	($0.64) per share	N/A
SMMT Summit Therapeutics	$700K	4,663.15	N/A	N/A	$0.11 per share	42.27

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASNS Arsanis	-$6.29M	-$2.76	N/A	∞	N/A	-112.13%	-667.48%	-52.43%	5/10/2024 (Estimated)
IDRA Idera Pharmaceuticals	$98.09M	-$0.32	N/A	N/A	N/A	N/A	-68.74%	-34.26%	N/A
PXS Pyxis Tankers	$37.04M	$2.96	1.66	∞	N/A	81.46%	45.81%	24.62%	5/20/2024 (Estimated)
RENE Cartesian Growth Co. II	$11.44M	N/A	0.00	∞	N/A	N/A	-65.59%	5.02%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.16	N/A	N/A	N/A	N/A	-125.07%	-51.02%	8/14/2024 (Estimated)

Latest ASNS, RENE, PXS, SMMT, and IDRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/15/2024	Q4 2023	PXS Pyxis Tankers	N/A	$1.76	+$1.76	$1.76	N/A	$13.25 million
3/26/2024	Q4 2023	ASNS Arsanis	N/A	-$0.67	-$0.67	-$0.67	N/A	$1.02 million
2/20/2024	Q4 2023	SMMT Summit Therapeutics	N/A	-$0.05	-$0.05	-$0.05	N/A	$0.20 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASNS Arsanis	N/A	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PXS Pyxis Tankers	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASNS Arsanis	13.77	0.86	0.49
IDRA Idera Pharmaceuticals	N/A	1.56	1.56
PXS Pyxis Tankers	0.55	6.04	5.94
RENE Cartesian Growth Co. II	N/A	0.22	0.22
SMMT Summit Therapeutics	2.26	6.97	6.97

Ownership

Institutional Ownership

Company	Institutional Ownership
ASNS Arsanis	12.43%
IDRA Idera Pharmaceuticals	12.18%
PXS Pyxis Tankers	56.19%
RENE Cartesian Growth Co. II	58.96%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ASNS Arsanis	14.21%
IDRA Idera Pharmaceuticals	5.05%
PXS Pyxis Tankers	54.60%
RENE Cartesian Growth Co. II	20.00%
SMMT Summit Therapeutics	83.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ASNS Arsanis	N/A	3.02 million	2.59 million	Not Optionable
IDRA Idera Pharmaceuticals	32	62.36 million	59.21 million	Optionable
PXS Pyxis Tankers	N/A	10.50 million	4.77 million	Not Optionable
RENE Cartesian Growth Co. II	N/A	21.62 million	17.30 million	Not Optionable
SMMT Summit Therapeutics	105	701.98 million	114.42 million	Optionable

ASNS, RENE, PXS, SMMT, and IDRA Headlines

Source	Headline
	Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Citigroup americanbankingnews.com - May 9 at 6:00 AM
	Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide seekingalpha.com - May 8 at 1:30 PM
	Summit Therapeutics (NASDAQ:SMMT) Sets New 1-Year High at $5.39 marketbeat.com - May 8 at 1:11 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Up 8.7% marketbeat.com - May 7 at 6:22 PM
	Summit spikes as Citi launches at Buy on lead asset msn.com - May 7 at 4:07 PM
	Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Citigroup marketbeat.com - May 7 at 7:30 AM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6% marketbeat.com - May 2 at 5:44 PM
	Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript finance.yahoo.com - May 2 at 1:16 PM
	Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... finance.yahoo.com - May 2 at 8:16 AM
	SMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024 investorplace.com - May 1 at 1:02 PM
	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 finance.yahoo.com - May 1 at 10:45 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading 3.6% Higher marketbeat.com - April 30 at 5:35 PM
	Summit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on Wednesday marketbeat.com - April 25 at 11:45 AM
	Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 businesswire.com - April 24 at 4:30 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Up 10.6% marketbeat.com - April 23 at 3:43 PM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6% marketbeat.com - April 13 at 7:47 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7% marketbeat.com - April 12 at 3:59 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors finance.yahoo.com - April 11 at 5:11 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors businesswire.com - April 11 at 4:30 PM
	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum businesswire.com - April 10 at 7:00 AM
	Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor reuters.com - April 9 at 4:33 PM
	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer prnewswire.com - April 9 at 4:05 PM
	Summit Therapeutics CEO acquires shares worth over $411k investing.com - March 29 at 8:13 PM
	Why Summit Therapeutics Stock Crushed the Market This Week fool.com - March 29 at 5:43 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arsanis

NASDAQ:ASNS

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

Idera Pharmaceuticals

NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Pyxis Tankers

NASDAQ:PXS

Pyxis Tankers Inc. operates as a maritime transportation company with a focus on the tanker sector worldwide. The company operates through Tanker Vessels and Dry-Bulk Vessels segments. Its fleet transports refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, and fuel oil, as well as other liquid bulk items, including vegetable oils and organic chemicals. As of March 29, 2024, the company operated a fleet of four tankers and two dry-bulk vessels. Pyxis Tankers Inc. was incorporated in 2015 and is based in Maroussi, Greece. Pyxis Tankers Inc. is a subsidiary of Maritime Investors Corp.

Cartesian Growth Co. II

NASDAQ:RENE

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.

Summit Therapeutics

NASDAQ:SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial